Genentech Expresses "Concern" About FDA Drug Approvals In McClellan’s Absence
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug approval timelines and FDA’s "spirit of urgency" could be impacted by the commissioner’s departure for CMS.